Noelia Pérez-Gómez, María Dolores Fernández-Ortega, Miren Elizari-Roncal, Estefanía Santos-Mazo, Laura de la Maza-Pereg, Sara Calvo, Raquel Alcaraz, Antonio Sanz-Solas, Raquel Vinuesa, Miriam Saiz-Rodríguez
{"title":"影响二甲双胍治疗2型糖尿病疗效的临床和药物遗传学因素的鉴定。","authors":"Noelia Pérez-Gómez, María Dolores Fernández-Ortega, Miren Elizari-Roncal, Estefanía Santos-Mazo, Laura de la Maza-Pereg, Sara Calvo, Raquel Alcaraz, Antonio Sanz-Solas, Raquel Vinuesa, Miriam Saiz-Rodríguez","doi":"10.2217/pgs-2023-0109","DOIUrl":null,"url":null,"abstract":"<p><p>Metformin, a hypoglycemic drug for Type 2 diabetes mellitus, shows variability in pharmacokinetics and response due to membrane transporters. This study followed 34 Type 2 diabetes mellitus patients on metformin treatment. Genetic variants in 11 metformin transport-related genes were analyzed, revealing associations. Specifically, <i>SLC47A1</i> rs2289669 A/A and <i>SLC22A4</i> rs1050152 T/T genotypes correlated with glycated hemoglobin values at 6 months. <i>SLC47A1</i> rs2289669 G/A genotype influenced glucose levels at 6 months, while <i>SLC29A4</i> rs3889348 A/A, <i>SLC47A1</i> rs2289669 A/A, <i>SLC22A4</i> rs1050152 C/T and <i>SLC47A2</i> rs12943590 A/A genotypes were linked to glucose levels at 12 months. Additionally, <i>ABCB1</i> rs2032582 C/A and <i>ABCG2</i> rs2231137 C/T genotypes impacted cholesterol levels at 12 months. These findings shed light on metformin response determinants, offering insights for further research.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"651-663"},"PeriodicalIF":1.9000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.\",\"authors\":\"Noelia Pérez-Gómez, María Dolores Fernández-Ortega, Miren Elizari-Roncal, Estefanía Santos-Mazo, Laura de la Maza-Pereg, Sara Calvo, Raquel Alcaraz, Antonio Sanz-Solas, Raquel Vinuesa, Miriam Saiz-Rodríguez\",\"doi\":\"10.2217/pgs-2023-0109\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Metformin, a hypoglycemic drug for Type 2 diabetes mellitus, shows variability in pharmacokinetics and response due to membrane transporters. This study followed 34 Type 2 diabetes mellitus patients on metformin treatment. Genetic variants in 11 metformin transport-related genes were analyzed, revealing associations. Specifically, <i>SLC47A1</i> rs2289669 A/A and <i>SLC22A4</i> rs1050152 T/T genotypes correlated with glycated hemoglobin values at 6 months. <i>SLC47A1</i> rs2289669 G/A genotype influenced glucose levels at 6 months, while <i>SLC29A4</i> rs3889348 A/A, <i>SLC47A1</i> rs2289669 A/A, <i>SLC22A4</i> rs1050152 C/T and <i>SLC47A2</i> rs12943590 A/A genotypes were linked to glucose levels at 12 months. Additionally, <i>ABCB1</i> rs2032582 C/A and <i>ABCG2</i> rs2231137 C/T genotypes impacted cholesterol levels at 12 months. These findings shed light on metformin response determinants, offering insights for further research.</p>\",\"PeriodicalId\":20018,\"journal\":{\"name\":\"Pharmacogenomics\",\"volume\":\" \",\"pages\":\"651-663\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacogenomics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/pgs-2023-0109\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/8/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0109","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.
Metformin, a hypoglycemic drug for Type 2 diabetes mellitus, shows variability in pharmacokinetics and response due to membrane transporters. This study followed 34 Type 2 diabetes mellitus patients on metformin treatment. Genetic variants in 11 metformin transport-related genes were analyzed, revealing associations. Specifically, SLC47A1 rs2289669 A/A and SLC22A4 rs1050152 T/T genotypes correlated with glycated hemoglobin values at 6 months. SLC47A1 rs2289669 G/A genotype influenced glucose levels at 6 months, while SLC29A4 rs3889348 A/A, SLC47A1 rs2289669 A/A, SLC22A4 rs1050152 C/T and SLC47A2 rs12943590 A/A genotypes were linked to glucose levels at 12 months. Additionally, ABCB1 rs2032582 C/A and ABCG2 rs2231137 C/T genotypes impacted cholesterol levels at 12 months. These findings shed light on metformin response determinants, offering insights for further research.
期刊介绍：
Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field.
Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
